Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2020 Dec 02

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Medica 2020 Dec 02

DOI: 10.23736/S0026-4806.20.07184-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Hepatitis C virus-associated Non-Hodgkin lymphomas: the endless history

Gabriele POZZATO 1 , Cesare MAZZARO 2, Valter GATTEI 2

1 Department of Clinical and Surgical Sciences, University of Trieste, Trieste, Italy; 2 Clinical and Experimental Onco-Haematology Unit, CRO Aviano National Cancer Institute IRCCS, Aviano, Pordenone, Italy


PDF


Hepatitis C virus (HCV) is a global population problem due to its high prevalence worldwide. In the prognosis of patients with HCV not only hepatic but increasingly frequent of extrahepatic HCV manifestations, such as mixed cryoglobulinemia (MC) and non-Hodgkin’s lymphoma (NHL), are important. The role of the HCV virus in the pathogenesis of lymphoproliferative diseases is confirmed by a large number of epidemiological studies, as well as by the effectiveness of antiviral therapy in patients with non-Hodgkin's lymphoma (NHL). The purpose of the review was to provide an overview of epidemiological and biological data explaining the role of HCV in the development of NHL. The review also discusses HCV-associated NHL treatment by the traditional antiviral therapy (interferon and ribavirin) and by the new direct antiviral agents.


KEY WORDS: Hepatitis C virus; Interferon; Ribavirin; non-Hodgkin's lymphoma; Direct antiviral agents

inizio pagina